Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma.
Blood Adv. 2022 Jun 14;6(11):3472-3479. doi: 10.1182/bloodadvances.2021006083.
Blood Adv. 2022.
PMID: 35390135
Free PMC article.
Clinical Trial.